Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Hansen; Hans J.
Address:
Picayune, MS
No. of patents:
62
Patents:


1 2










Patent Number Title Of Patent Date Issued
8574575 RS7 antibodies November 5, 2013
This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target
8568729 Anthracycline-antibody conjugates for cancer therapy October 29, 2013
The invention relates to therapeutic conjugates with the ability to target various antigens. The conjugates contain a targeting antibody or antigen binding fragment thereof and an anthracycline chemotherapeutic drug. The targeting antibody and the chemotherapeutic drug are linked via
8287865 Class I anti-CEA antibodies and uses thereof October 16, 2012
The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID
8287864 Structural variants of antibodies for improved therapeutic characteristics October 16, 2012
The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fusion proteins or
8268312 Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof September 18, 2012
The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and dia
8216572 Antibody therapy July 10, 2012
The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
8192739 Fusion proteins containing recombinant cytotoxic RNAses June 5, 2012
Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ab
8188239 Multivalent carriers of bi-specific antibodies May 29, 2012
Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targeta
8168186 Therapeutic using a bispecific antibody May 1, 2012
Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, au
8163887 Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines April 24, 2012
Humoral and cellular immune responses against tumor cells and infectious agents are induced in a mammal using a vaccine comprising immunoconjugates that comprise antibodies and anti-idiotype antibodies that mimic an epitope of an antigen that is associated with a tumor or an infectio
8158573 Therapeutic and diagnostic conjugates for use with multispecific antibodies April 17, 2012
Disclosed are compounds that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histimine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compound also includes an effector molecule which may
8147831 Anti-CD19 antibodies April 3, 2012
The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various
8119101 Anti-CD74 immunoconjugates and methods of use February 21, 2012
Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle.
8097252 Methods and compositions for administering therapeutic and diagnostic agents January 17, 2012
Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.
8084583 RS7 antibodies December 27, 2011
This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target
8084029 Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof December 27, 2011
The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and dia
8062636 Antibody therapy November 22, 2011
The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
8017736 Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof September 13, 2011
The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and dia
7951921 Multivalent carriers of bi-specific antibodies May 31, 2011
Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targeta
7951369 Chimeric, human and humanized anti-granulocyte antibodies and methods of use May 31, 2011
The present invention provides humanized, chimeric and human MN3 antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of granulocy
7943343 Production and use of novel peptide-based agents for use with bi-specific antibodies May 17, 2011
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodie
7931903 Internalizing anti-CD74 antibodies and methods of use April 26, 2011
The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and
7931890 Targeted combination immunotherapy of cancer and infectious diseases April 26, 2011
The present invention is directed to methods for treating cancer wherein more than one therapeutic agent is used, with each of the therapeutic agents having different tumor-killing capabilities, and wherein the therapeutic agents are delivered to the tumor sites using combined target
7919273 Structural variants of antibodies for improved therapeutic characteristics April 5, 2011
The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fusion proteins or
7919090 Antibody therapy April 5, 2011
The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
7914787 Production and use of novel peptide-based agents with bispecific antibodies March 29, 2011
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which compris
7902338 Anti-CD19 antibodies March 8, 2011
The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various
7892547 Methods and compositions for administering therapeutic and diagnostic agents February 22, 2011
Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.
7833528 Use of multispecific, non-covalent complexes for targeted delivery of therapeutics November 16, 2010
Embodiments of the invention relate to a method for treating target cells, tissues or pathogens in a subject, comprising administering a non-covalently bound complex which comprises a multispecific targeting protein and a hapten-enzyme covalent conjugate, followed by administration o
7829064 Anti-CD74 immunoconjugates and methods November 9, 2010
Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit f
7820164 Chimeric, human and humanized anti-CSAP monoclonal antibodies October 26, 2010
The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.
7803372 Antibody therapy September 28, 2010
The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
7772373 Internalizing anti-CD74 antibodies and methods of use August 10, 2010
The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and
7670804 Chimeric, human and humanized anti-CSAP monoclonal antibodies March 2, 2010
The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.
7666415 Production and use of novel peptide-based agents for use with bi-specific antibodies February 23, 2010
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodie
7662378 Antibody therapy February 16, 2010
The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
7641901 Immunotherapy of autoimmune disorders using antibodies which target B-cells January 5, 2010
Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly
7641891 Chimeric, human and humanized anti-CSAp monoclonal antibodies January 5, 2010
The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.
7612180 Humanized L243 antibodies November 3, 2009
Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapuetic and diagn
7563439 Production and use of novel peptide-based agents for use with bi-specific antibodies July 21, 2009
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been pr
7560110 Production and use of novel peptide-based agents with bispecific antibodies July 14, 2009
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which compris
7553953 Chimeric, human and humanized anti-CSAp monoclonal antibodies June 30, 2009
The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.
7544487 Fusion proteins containing recombinant cytotoxic RNAses June 9, 2009
Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ab
7541440 Chimeric, human and humanized anti-granulocyte antibodies and methods of use June 2, 2009
The present invention provides humanized, chimeric and human MN3 antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of granulocy
7534431 Methods and compositions for administering therapeutic and diagnostic agents May 19, 2009
Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.
7534427 Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and c May 19, 2009
The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically a
7514066 Targeted combination immunotherapy of cancer and infectious diseases April 7, 2009
The present invention is directed to methods for treating cancer wherein more than one therapeutic agent is used, with each of the therapeutic agents having different tumor-killing capabilities, and wherein the therapeutic agents are delivered to the tumor sites using combined target
7501498 Alpha-fetoprotein Immu31 antibodies and fusion proteins March 10, 2009
The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and dia
7462352 Methods of treatng B-cell diseases using humanized anti-CD19 antibodies December 9, 2008
The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various
7429381 Production and use of novel peptide-based agents for use with bi-specific antibodies September 30, 2008
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been pr
1 2










 
 
  Recently Added Patents
Configuration and incentive in event management environment providing an automated segmentation of consideration
Analysis of stress impact on transistor performance
Engineered magnetic layer with improved perpendicular anisotropy using glassing agents for spintronic applications
Composition for enhancing memory and mitigating neurodegeneration and method thereof
Positioning vehicles to improve quality of observations at intersections
Approaching object detection system
Diaminocyclohexane compounds and uses thereof
  Randomly Featured Patents
Detecting leakage of engine exhaust gas using exhaust mass flow measurement
Systems and methods for impact testing
X-ray arrangement and x-ray contrast process for imaging an object under examination that contains at least one radiopaque element as well as use of the x-ray arrangement
Selective delivery and retention of aldehyde and nicotine by-product from cigarette smoke
Transaction system and method
Electron beam lithography system having variable writing speed
Work piece holding device
One-component-type composition for polyurethane elastomer and method for processing the same by molding
Child safety seat
Electrically controllable window treatment system to control sun glare in a space